Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer

Complement and Its Receptors: New Insights into Human Disease

(2014) V. Michael Holers   Annual Review of Immunology

A Novel Non-Synonymous Polymorphism (p.Arg240His) in C4b-Binding Protein Is Associated with Atypical Hemolytic Uremic Syndrome and Leads to Impaired Alternative Pathway Cofactor Activity

(2014) Anna M. Blom et al.   JOURNAL OF IMMUNOLOGY

Experimental Antibody Therapy of Liver Metastases Reveals Functional Redundancy between Fc RI and Fc RIV

(2014) M. A. Otten et al.   JOURNAL OF IMMUNOLOGY

Complement Is Activated by IgG Hexamers Assembled at the Cell Surface

(2014) C. A. Diebolder et al.   SCIENCE

An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

(2013) Thies Rösner et al.   BRITISH JOURNAL OF HAEMATOLOGY

Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells

(2013) S. Horl et al.   HAEMATOLOGICA

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

(2013) S Hörl et al.   LEUKEMIA

GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present

(2013) Delila J. Kern et al.   LEUKEMIA & LYMPHOMA

The role of complement in mAb-based therapies of cancer

(2013) Ronald P. Taylor et al.   METHODS

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab

(2013) Srinivas Mamidi et al.   Molecular Oncology

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

(2012) Bridget Charbonneau et al.   AMERICAN JOURNAL OF HEMATOLOGY

Boosting antibody therapy with complement

(2012) P. Boross et al.   BLOOD

A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer

(2012) M. Elvington et al.   BLOOD

Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy

(2012) D. Xiang et al.   CURRENT MEDICINAL CHEMISTRY

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement

(2012) Nisar A. Baig et al.   LEUKEMIA & LYMPHOMA

Transient Removal of CD46 Is Safe and Increases B-cell Depletion by Rituximab in CD46 Transgenic Mice and Macaques

(2012) Ines Beyer et al.   MOLECULAR THERAPY

Human CD59 Inhibitor Sensitizes Rituximab-Resistant Lymphoma Cells to Complement-Mediated Cytolysis

(2011) W. Hu et al.   CANCER RESEARCH

rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

(2011) X. Ge et al.   CLINICAL CANCER RESEARCH

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

(2011) P. Boross et al.   HAEMATOLOGICA

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

(2011) Masami Kadowaki et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

(2011) Nigel M. Stapleton et al.   Nature Communications

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

(2010) N. Geis et al.   CURRENT CANCER DRUG TARGETS

Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

(2010) Wei Xu et al.   INTERNATIONAL JOURNAL OF CANCER

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

(2010) Gregory L. Moore et al.   mAbs

Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma

(2009) Abraham Klepfish et al.   Annals of the New York Academy of Sciences

Complement in antibody therapy: friend or foe?

(2009) M. Introna et al.   BLOOD

Complement: help or hindrance?

(2009) S. A. Beers et al.   BLOOD

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model

(2009) Yanping Hu et al.   IMMUNOLOGY

The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35)

(2009) Dong Liu et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging

(2009) Arnout F. Gerritsen et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Complement in human diseases: Lessons from complement deficiencies

(2009) Marina Botto et al.   MOLECULAR IMMUNOLOGY

Therapeutic potential of complement modulation

(2009) Eric Wagner et al.   NATURE REVIEWS DRUG DISCOVERY

C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress

(2009) Massimo Cugno et al.   TRENDS IN MOLECULAR MEDICINE

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

(2008) S. A. Beers et al.   BLOOD

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

The possible role of factor H in colon cancer resistance to complement attack

(2008) Ewa Wilczek et al.   INTERNATIONAL JOURNAL OF CANCER